# Liquidia (LQDA): Settles all six lawsuits with United Therapeutics for a net $380.7M

> Liquidia has settled all six lawsuits with rival United Therapeutics, so its lung drug Yutrepia can stay on sale for a disease called PAH. The price…

- URL: https://centiview.com/post/liquidia-lqda-settles-all-six-lawsuits-with-united-therapeutics-for-a-net-380-7m
- Published: 2026-10-14T17:10:00.000Z
- Sectors: Healthcare
- Region: US
- Ticker: LQDA
- Sentiment (opinion, not a recommendation): neutral
- Publisher: Centiview (Persie Ltd, London)
- General information only, not financial advice

Liquidia has settled all six lawsuits with rival United Therapeutics, so its lung drug Yutrepia can stay on sale for a disease called PAH. The price is a net $380.7M, paid in 2026 and 2027, and Liquidia must stop promoting the drug for a second lung condition, PH-ILD. Early sales for Q3 were $222.7M and cash was $396.1M.

> **Why it matters** The deal removes the risk that a court ruling could force Yutrepia off the market, but it costs real money and limits where Liquidia can sell the drug.

> **What we verified** The six-lawsuit settlement, the PH-ILD label removal, the payment schedule, $222.7M of early Q3 sales and $396.1M cash come from Liquidia's SEC 8-K dated October 13, 2026. United Therapeutics' own 8-K confirms the payment dates and PH-ILD limits, and Investing.com reports the same net $380.7M.

### Sources
- [Liquidia 8-K: global settlement press release (SEC)](https://www.sec.gov/Archives/edgar/data/0001819576/000110465926115672/tm2627557d1_ex99-1.htm)
- [United Therapeutics 8-K (SEC)](https://www.sec.gov/Archives/edgar/data/0001082554/000110465926115723/tm2627546d1_8k.htm)
- [Why is Liquidia stock surging today? (Investing.com)](https://www.investing.com/news/stock-market-news/why-is-liquidia-stock-surging-today-93CH-4948425)